NCT05084495Completed
The Use of Flecainide for Treatment of Atrial Fibrillation
Can Global Peak Longitudinal Strain Measurements in Combination With Non-invasive ECG Parameters Predict the Success or Failure of Flecainide Treatment for Atrial Fibrillation Patients?
Source: ClinicalTrials.gov · Last updated 11 Sept 2025
Brief summary (registry, in English)
This prospective observational study will include patients with atrial fibrillation that has indication for treatement with flecainide. Included patients are followed during a 12 month period. During the follow-up period they will have four clinical visits, during which clinical data, advanced echocardiographic data (strain and speckle tracking) and ECGs (Glasgow criteria) will be collected. These data will be analysed in relation to outcome parameters as: maintaining a normal sinus rhythm (arrythmia free health status), number of AF-free months, chances of successful electrical cardioversion, frequency of side effects, risk of pro-arrhythmias and mortality. The importance of these two analyses is to improve the use of flecainide. Hence, today patients with low benefit compared to risk of adverse events are inappropriately treated with flecainide with the "trial and error" approach currently used. On the other hand flecainide is currently underutilized, and patients denied the treatment that could improve their quality of life, prognosis and reduce their risk of cardiovascular adverse events. By investigating novel and promising parameters there is the potential of a better prediction of initiating safe and accurate anti-arrhythmic therapy for patients with atrial fibrillation.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 50 (actual)
- First submitted
- 18 Oct 2021
- Start date
- 1 Feb 2022
- Primary completion date
- 15 Apr 2025
- Lead sponsor
- Lund University
- Diseases
- Atrial fibrillation
- NCT number
- NCT05084495
What you commit to
- Study type: Observational
- Participants enrolled: 50
- From 1 Feb 2022 to the primary completion date, 15 Apr 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Flecainide treatment with other indication than atrial fibrillation (including atrial flutter).
Age
- Age \<18 years
Other
- No secure date for treatment start.
Who the study is looking for
- All patients with written informed consent who are eligible for flecainide treatment for atrial fibrillation.
- The patients must be followed at the Skånes hospitals northwest and Skånes university hospitals.
- Age \>18 years
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Clinical Sciences, Helsingborg Medical Faculty Lund University Coordinator of this site? Confirm its status | Helsingborg | Sweden | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.